Eli Lilly and Company (LLY)
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here's why
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company's prior guidance and includes $3.5 billion from its type 2 diabetes drug Mounjaro and $1.9 billion from its weight-loss medication Zepbound.
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip
Eli Lilly slashes the revenue guidance for the fourth quarter and fiscal 2024 but offers a bullish outlook for 2025.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4
LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates.
Buy, Sell, Or Hold LLY Stock At $750?
Eli Lilly stock (NYSE: LLY) fell over 6% on Tuesday, January 14, after it announced that the sales of its obesity drugs are seeing slower than anticipated growth. It has adjusted its Q4 revenue forecast downward by 5% to $13.5 billion, falling $500 million short of analysts' consensus estimate of $14 billion.
Has Eli Lilly Stock Peaked?
Eli Lilly (LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first healthcare company to top a $1 trillion valuation, perhaps as early as this year.
Here's why Eli Lilly stock is crashing
Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 revenue guidance, which fell short of Wall Street expectations.
Watch These Eli Lilly Price Levels as Stock Slumps on Tepid Sales Outlook
Eli Lilly (LLY) shares could remain under the microscope on Wednesday after falling sharply in trade on Tuesday as the pharmaceutical giant lowered its 2024 full-year revenue forecast.
Eli Lilly and Company (LLY) CEO Dave Ricks presents at 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Eli Lilly and Company (NYSE:LLY ) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ET Company Participants Dave Ricks - Chairman and CEO Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody.
Buy the weakness in Eli Lilly, says Mizuho Healthcare Strategist Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk how to play Eli Lilly's stock right now.
Eli Lilly Stock Slumps on Lowered Sales Forecast
Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year.
